BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 25341796)

  • 1. Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9.
    Roche-Molina M; Sanz-Rosa D; Cruz FM; García-Prieto J; López S; Abia R; Muriana FJ; Fuster V; Ibáñez B; Bernal JA
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):50-9. PubMed ID: 25341796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
    Lu H; Howatt DA; Balakrishnan A; Graham MJ; Mullick AE; Daugherty A
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1753-7. PubMed ID: 27470509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of atherosclerosis in mice and hamsters without germline genetic engineering.
    Bjørklund MM; Hollensen AK; Hagensen MK; Dagnaes-Hansen F; Christoffersen C; Mikkelsen JG; Bentzon JF
    Circ Res; 2014 May; 114(11):1684-9. PubMed ID: 24677271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia.
    Cansby E; Magnusson E; Nuñez-Durán E; Amrutkar M; Pedrelli M; Parini P; Hoffmann J; Ståhlman M; Howell BW; Marschall HU; Borén J; Mahlapuu M
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1723-1737. PubMed ID: 29930001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
    Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
    J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of Nicotinamide Nucleotide Transhydrogenase in C57BL/6J Mice Exacerbates Experimental Atherosclerosis.
    Vozenilek AE; Vetkoetter M; Green JM; Shen X; Traylor JG; Klein RL; Orr AW; Woolard MD; Krzywanski DM
    J Vasc Res; 2018; 55(2):98-110. PubMed ID: 29455203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia.
    Somanathan S; Jacobs F; Wang Q; Hanlon AL; Wilson JM; Rader DJ
    Circ Res; 2014 Aug; 115(6):591-9. PubMed ID: 25023731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local effects of human PCSK9 on the atherosclerotic lesion.
    Giunzioni I; Tavori H; Covarrubias R; Major AS; Ding L; Zhang Y; DeVay RM; Hong L; Fan D; Predazzi IM; Rashid S; Linton MF; Fazio S
    J Pathol; 2016 Jan; 238(1):52-62. PubMed ID: 26333678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerating the pace of atherosclerosis research.
    Daugherty A; Tabas I; Rader DJ
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):11-2. PubMed ID: 25520521
    [No Abstract]   [Full Text] [Related]  

  • 11. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway.
    Tang ZH; Peng J; Ren Z; Yang J; Li TT; Li TH; Wang Z; Wei DH; Liu LS; Zheng XL; Jiang ZS
    Atherosclerosis; 2017 Jul; 262():113-122. PubMed ID: 28535426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.
    Denis M; Marcinkiewicz J; Zaid A; Gauthier D; Poirier S; Lazure C; Seidah NG; Prat A
    Circulation; 2012 Feb; 125(7):894-901. PubMed ID: 22261195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research.
    Jarrett KE; Lee C; De Giorgi M; Hurley A; Gillard BK; Doerfler AM; Li A; Pownall HJ; Bao G; Lagor WR
    Arterioscler Thromb Vasc Biol; 2018 Sep; 38(9):1997-2006. PubMed ID: 30026278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification.
    Goettsch C; Hutcheson JD; Hagita S; Rogers MA; Creager MD; Pham T; Choi J; Mlynarchik AK; Pieper B; Kjolby M; Aikawa M; Aikawa E
    Atherosclerosis; 2016 Aug; 251():109-118. PubMed ID: 27318830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing Vascular Calcification by Anti-IL-1β Monoclonal Antibody in a Mouse Model of Familial Hypercholesterolemia.
    Awan Z; Denis M; Roubtsova A; Essalmani R; Marcinkiewicz J; Awan A; Gram H; Seidah NG; Genest J
    Angiology; 2016 Feb; 67(2):157-67. PubMed ID: 25904765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control.
    Herbert B; Patel D; Waddington SN; Eden ER; McAleenan A; Sun XM; Soutar AK
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1333-9. PubMed ID: 20448210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
    Hurt-Camejo E; Gautier T; Rosengren B; Dikkers A; Behrendt M; Grass DS; Rader DJ; Tietge UJ
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2707-14. PubMed ID: 24115030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
    Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
    Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
    Stawowy P; Just IA; Kaschina E
    Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.